These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39001729)

  • 1. Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events.
    Zhao K; Zhu Y; Chen X; Yang S; Yan W; Yang K; Song Y; Cui C; Xu X; Zhu Q; Cui ZX; Yin G; Cheng H; Lu M; Liang D; Shi K; Zhao L; Liu H; Zhang J; Chen L; Prasad SK; Zhao S; Zheng H
    JACC Cardiovasc Imaging; 2024 Aug; 17(8):880-893. PubMed ID: 39001729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
    Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
    J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
    Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 7. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
    Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy: The STRAIN-HCM study.
    Negri F; Muser D; Driussi M; Sanna GD; Masè M; Cittar M; Poli S; De Bellis A; Fabris E; Puppato M; Grigoratos C; Todiere G; Aquaro GD; Sinagra G; Imazio M
    Int J Cardiol; 2021 Dec; 345():61-67. PubMed ID: 34728259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy.
    Yang S; Zhao K; Yang K; Song J; Yu S; Wang J; Dong Z; Ma X; Yin G; Li J; Cheng H; Lu M; Chen X; Zhao S
    JACC Cardiovasc Imaging; 2023 Sep; 16(9):1163-1177. PubMed ID: 37204388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional prognostic values of strain and strain rate over late gadolinium enhancement in hypertrophic cardiomyopathy patients.
    Qin L; Zhu S; Liu P; Zhu L; Chen C; Gu S; Yang W; Zhou M; Yan F
    Int J Cardiol; 2023 Jan; 370():427-434. PubMed ID: 36332750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
    Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
    JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.
    Cheng S; Choe YH; Ota H; Cui C; Yin G; Lu M; Li L; Chen X; Prasad SK; Zhao S
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):597-605. PubMed ID: 29071521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Feasibility of Left Ventricular Strain and Strain Rate for Evaluating Hypertrophic Cardiomyopathy with Risk Factors of Sudden Cardiac Death by Feature-Tracking CMR.
    Zhu X; Tian Y; Shi Y; Lian J; Shen H; Li L; Wu H; Liu P
    Am J Cardiol; 2024 Jul; 222():51-57. PubMed ID: 38642869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.